X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (63) 63
humans (60) 60
female (45) 45
male (40) 40
ophthalmology (35) 35
adult (31) 31
middle aged (31) 31
aged (29) 29
article (27) 27
abridged index medicus (24) 24
clinical trials (23) 23
aged, 80 and over (18) 18
care and treatment (17) 17
risk factors (16) 16
treatment outcome (15) 15
follow-up studies (14) 14
research (12) 12
analysis (10) 10
drug abuse (10) 10
health aspects (10) 10
prospective studies (10) 10
retinal vein occlusion - complications (10) 10
retinal vein occlusion - drug therapy (10) 10
substance abuse (10) 10
visual acuity (10) 10
macular edema - etiology (9) 9
psychiatry (9) 9
retina (9) 9
tomography, optical coherence (9) 9
bevacizumab (8) 8
glucocorticoids - administration & dosage (8) 8
intravitreal injections (8) 8
macular edema - drug therapy (8) 8
open-angle glaucoma (8) 8
patients (8) 8
retinal diseases (8) 8
risk-factors (8) 8
triamcinolone acetonide - administration & dosage (8) 8
usage (8) 8
edema (7) 7
glaucoma, open-angle - surgery (7) 7
incidence (7) 7
injections (7) 7
obstetrics & gynecology (7) 7
prevalence (7) 7
public health (7) 7
retrospective studies (7) 7
safety (7) 7
acuity (6) 6
children (6) 6
cohort studies (6) 6
corticosteroids (6) 6
drug therapy (6) 6
eye diseases (6) 6
immunology (6) 6
macular edema - diagnosis (6) 6
macular edema - physiopathology (6) 6
medical research (6) 6
pharmacology & pharmacy (6) 6
retinal vein occlusion - diagnosis (6) 6
time factors (6) 6
trabeculectomy (6) 6
visual acuity - physiology (6) 6
visual fields (6) 6
vitreous body (6) 6
age (5) 5
clinical trial (5) 5
diabetic-retinopathy (5) 5
diagnosis (5) 5
efficacy (5) 5
eye (5) 5
fluorescein angiography (5) 5
glaucoma (5) 5
glucocorticoids - therapeutic use (5) 5
intraocular pressure (5) 5
medical colleges (5) 5
medicine, experimental (5) 5
medicine, general & internal (5) 5
medicine, research & experimental (5) 5
occlusion (5) 5
pregnancy (5) 5
prognosis (5) 5
progression (5) 5
randomized-trial (5) 5
ranibizumab (5) 5
regression analysis (5) 5
retina - pathology (5) 5
retinal vein occlusion - therapy (5) 5
studies (5) 5
substance abuse treatment (5) 5
substance use (5) 5
substance use disorder (5) 5
united states (5) 5
vascular endothelial growth factor (5) 5
viral load (5) 5
young adult (5) 5
abuse (4) 4
adults (4) 4
african continental ancestry group (4) 4
blindness (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 04/2018, Volume 136, Issue 4, p. 337
Importance Comparisons of monthly vs treat-and-extend anti–vascular endothelial growth factor (anti-VEGF) regimens for macular edema from central retinal vein... 
Macular degeneration | Occlusion | Edema | Retinopathy | Diabetes mellitus | Clinical trials | Eye diseases | Retina | Ophthalmology | Vascular endothelial growth factor | Acuity | Bevacizumab
Journal Article
JAMA, ISSN 0098-7484, 05/2017, Volume 317, Issue 20, pp. 2072 - 2087
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 09/2015, Volume 133, Issue 9, p. 1022
  The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at... 
Injections | Clinical trials | Eye diseases | Ophthalmology | Drug therapy | Eyes & eyesight | Risk factors
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 2018, Volume 137, Issue 3, pp. 281 - 287
IMPORTANCE. Information is needed to assess switching treatment in eyes with a poor response to 6 months of monthly administration of aflibercept or... 
OPHTHALMOLOGY | RANIBIZUMAB | THERAPY | Occlusion | Eye | Edema | Dexamethasone | Retina | Ophthalmology | Acuity | Bevacizumab | Index Medicus | Abridged Index Medicus
Journal Article
JAMA Ophthalmology, ISSN 2168-6165, 06/2017, Volume 135, Issue 6, pp. 639 - 649
Journal Article
Retina, ISSN 0275-004X, 05/2018, p. 1
PURPOSERepackaged bevacizumab in single-dose, prefilled syringes for intravitreal injection is available, but with shelf life limited from 60 days to 90 days.... 
Journal Article
JAMA OPHTHALMOLOGY, ISSN 2168-6165, 08/2018, Volume 136, Issue 8, pp. 849 - 856
IMPORTANCE There are no approved drug treatments for autosomal dominant retinitis pigmentosa, a relentlessly progressive cause of adult and childhood... 
FIELD FUNDUS AUTOFLUORESCENCE | DYSTROPHY | PERIMETRY | DOCOSAHEXAENOIC ACID | OPHTHALMOLOGY | RHODOPSIN MUTATIONS | PROGRESSION | Online First | Original Investigation | Research
Journal Article